drugset / Trial / NCT07804498

CITADEL: Effectiveness of CITicoline in Preventing Cognitive Decline After DELirium

NCT07804498 ↗

Phase 2 Recruiting 122 enrolled University of Milano Bicocca
RandomizedParallel-groupSingle-blindPrevention

Summary

The aim of this study is to assess whether citicoline (TRAUSAN), a neuroprotective agent involved in membrane phospholipid synthesis and neurotransmission, can prevent or attenuate cognitive decline in older adults who develop perioperative delirium during hospitalization for proximal hip fracture. Delirium is a frequent and severe complication in this population and is associated with cognitive and functional deterioration, institutionalization, and mortality. Participants will be randomly assigned (1:1) to receive citicoline 1000 mg/day for 6 months after discharge, or usual care. Cognitive and functional status will be evaluated at discharge and subsequently at 3 and 6 months follow-up visits.

Timeline

Start
2026-06-03
Primary completion
2027-12-05
Completion
2027-12-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Citicoline Other / unclassified 1000 mg Oral

Indications